BTIG Rates Natera (NTRA) buy, $275 Price Target

BTIG has reaffirmed its buy rating on Natera, Inc., setting a price target of $275, a 5% upside from the current price.

By EarningsIQ Research Desk · Published Jun 24, 2026, 2:02 PM EDT · Updated Jun 29, 2026, 9:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

BTIG rated Natera, Inc. ($NTRA) "buy" with a $275 price target on June 24, 2026.

Since the rating, $NTRA is up 6.3% after 1 week, up 0.8% after 1 month and up 51.3% to date (from the $259.97 close on Jun 24, 2026).

NTRA Natera, Inc.

$393.44 +71.93% year to date

Daily close · Oct 16, 2026

Key Points

BTIG reiterated its buy rating on Natera, Inc. with a new price target of $275 on June 24, 2026.
BTIG's $275 price target implies 5% upside from Natera, Inc.'s ($NTRA) current $261.91 share price.
Natera's stock is currently trading at $261.91, which is below the new target, indicating potential for growth.
Analysts generally favor Natera, with a consensus recommendation of 'strong buy' and a mean price target of $348.02.

Get $NTRA trade alerts by text

We text you when insiders, Congress or big funds trade $NTRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures

Analysts Set New Price Targets

On June 24, 2026, BTIG reiterated its buy rating on Natera, Inc. (NasdaqGS: NTRA), setting a new price target of $275. This new target reflects an optimistic outlook for the diagnostics company, especially as the stock currently trades at $261.91.

Analyst rating track record

BTIG vs. the S&P 500

YTD return -22.78% hypothetical

All-time return +26.43% S&P 500 +38.43%

vs. S&P 500 -12% behind the index

Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.

What This Means for Natera

The reaffirmed rating comes as Natera's shares are priced below the new target, suggesting that analysts see room for the stock to rise. The market capitalization of Natera is approximately $53.43 billion, and the company operates in the healthcare sector, specifically in diagnostics and research. Natera's innovative testing services, including cancer screening and prenatal tests, play a crucial role in its growth strategy.

Institutional Insights

While no peer fund movements were reported in this instance, Natera's strong positioning in the diagnostics market has drawn attention from multiple analysts. In the past, firms like JP Morgan and Morgan Stanley have maintained their ratings on the stock, with JP Morgan recently raising its price target to $460 on October 14, 2026. This strong support from various analysts highlights the confidence in Natera's potential.

How Natera, Inc. Stock Has Traded

Natera's stock has seen fluctuations in the past year, with a 52-week low of $157.43 and a high of $373.07. The current trading price of $261.91 is significantly below both the 52-week high and the 200-day moving average of $241.36, indicating a potential rebound opportunity for investors. The stock's beta of 1.53 suggests it is more volatile than the broader market, which could present both risks and opportunities.

12-month forecast

$NTRA price target

Natera, Inc. daily closes and this analyst's $275 target. Not advice.

Analysts Set New Price Targets

The consensus opinion among analysts is a strong buy, with a mean price target of $348.02 based on 23 opinions. Other firms, including Citigroup and TD Cowen, have also maintained their positive outlook, with targets set at $480 and $480 respectively. These ratings reflect a collective confidence in Natera's long-term growth potential.

What Natera, Inc. Does

Natera, Inc. is a diagnostics company that provides a wide range of molecular testing services globally. Its offerings include blood tests for cancer and prenatal screening, which are critical in modern healthcare. The company's innovative approach and strong market presence make it a key player in the diagnostics industry.

What's Ahead for Natera, Inc.

Investors will be watching for Natera's next earnings report, scheduled for November 5, 2026, which could shed light on the company's financial health and operational performance. The 13F filings will also provide insights into institutional holdings, reflecting the market's sentiment towards Natera as new information becomes available.